Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Gaithersburg, MD.
相关临床试验
2
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2015
进行中（未招募）
1
50.0%
招募中
1
50.0%
暂无批准数据
- Oryon Cell Therapies has appointed Kenny Choi, Ph.D., as Chief Technical Officer to lead technical operations and CMC strategy for its autologous neuron replacement medicines. - Dr. Choi brings more than fifteen years of cell therapy manufacturing experience, contributing to over a dozen INDs and three BLAs for autologous cell therapies. - He will oversee transfer of the autologous iPSC-derived dopaminergic neuron manufacturing process from Mass General Brigham to Oryon's own facilities for late-stage development and commercial launch. - Oryon's lead program is in a Phase 1/2a trial for Parkinson's disease, with interim data showing sustained motor improvements in all treated participants.
- Gilead is leveraging its virology legacy to build a leading oncology portfolio centered on antibody-drug conjugates (ADCs) and CAR T-cell therapies, with Chief Medical Officer Dietmar Berger targeting top 10 or top 5 oncology company status within a few years. - Recent acquisitions of Tubulis (next-generation ADC platform), Interius (in vivo CAR T-cell therapy), and a multiple myeloma-focused company are strategically expanding Gilead's pipeline across both solid tumors and hematologic cancers. - Kite, a Gilead company, has now treated over 34,500 patients worldwide with its cell therapies and maintains an industry-leading 96% manufacturing success rate through its fully integrated in-house manufacturing network. - Despite Kite's leadership, only about 2 out of 10 eligible patients currently obtain CAR-T therapy, highlighting a significant access gap the company is working to address by expanding its 600 authorized treatment centers globally.
- Intravacc and Primrose Bio have renewed their strategic partnership to enhance conjugate vaccine development and manufacturing capabilities for third-party clients. - The collaboration combines Intravacc's expertise in vaccine conjugation and GMP production with Primrose Bio's PeliCRM197® carrier protein technology. - The partnership creates a seamless full-service solution spanning from early-stage development through clinical manufacturing for vaccine developers. - PeliCRM197® represents the only CRM197 carrier protein used in commercial vaccines that is available for purchase, offered in research and GMP grades.
- Century Therapeutics appointed Dr. Han Lee and Dr. Martin Murphy to its Board of Directors to provide strategic oversight as the company advances its iPSC-derived cell therapy programs. - Dr. Lee brings extensive capital formation and corporate development experience from leadership roles at ImmPACT Bio, Neogene Therapeutics, and Arcellx. - Dr. Murphy contributes significant life science investment expertise as co-founder of Syncona Limited and current board positions at multiple biotech companies. - The appointments come as Century focuses on bringing CNTY-813, a potential curative treatment for type 1 diabetes, and other pipeline candidates closer to clinical trials.
- The FDA is raising approval standards for CAR-T therapies by requiring randomized controlled trials with survival or time-to-event endpoints as the preferred approach for regulatory filings. - Single-arm trials, which supported all seven currently approved CAR-T therapies, will no longer be sufficient for full approval, though they may still support accelerated approval in rare cancers. - Companies must now test experimental CAR-T therapies against existing standard treatments, including other approved CAR-T products, with control groups selected based on available treatments and ethical considerations. - The regulatory shift adds pressure to an already challenged cell therapy sector that has seen recent high-profile exits and discontinuations from companies like Regeneron and Cargo Therapeutics.
- Kite and Arcellx announced positive results from the pivotal iMMagine-1 Phase 2 study of anito-cel, showing a 96% overall response rate in heavily pretreated relapsed or refractory multiple myeloma patients. - The CAR T-cell therapy demonstrated deep responses with 74% achieving stringent complete response and 95% achieving minimal residual disease negativity at median 15.9-month follow-up. - Safety profile was manageable with no delayed neurotoxicities observed, and the companies plan a 2026 U.S. launch for this BCMA-directed therapy. - Progression-free survival rates were 82.1% at 12 months and 61.7% at 24 months, with median survival endpoints not yet reached in this advanced patient population.
- Arcellx's lead CAR-T therapy anitocel achieved a 97% overall response rate and 93.1% minimal residual disease-negative responses in Phase 2 trials for multiple myeloma. - The therapy demonstrated a favorable safety profile, avoiding severe neurotoxicity commonly associated with CAR-T treatments, with over 150 patients treated. - The company has updated its iMMagine-3 study protocol to include MRD negativity alongside progression-free survival as dual primary endpoints to accelerate regulatory approval. - Arcellx targets a 2026 commercial launch for anitocel and has expanded its partnership with Kite to co-develop CAR-T programs for multiple myeloma and lymphoma.
- Arcellx's lead CAR-T therapy anito-cel achieved a 97% overall response rate and 93.3% minimal residual disease negativity in 117 multiple myeloma patients from the Phase 2 iMMagine-1 study. - The company's Q2 2025 collaboration revenue dropped 72% to $7.6 million, missing analyst expectations by 43.8% due to completion of clinical trial manufacturing activities. - Net loss more than doubled to $52.8 million as the company increased commercial readiness spending ahead of a planned 2026 product launch. - FDA authorized an investigational new drug application for ACLX-004, expanding Arcellx's pipeline into acute myeloid leukemia treatment.
- Arcellx's Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel) demonstrated a 97% overall response rate and 68% complete response rate in 117 patients with relapsed/refractory multiple myeloma. - The CAR-T therapy showed a favorable safety profile with no delayed neurotoxicities, Parkinsonism, cranial nerve palsies, Guillain-Barré syndrome, or immune-mediated enterocolitis observed to date. - Developed in partnership with Kite (Gilead), anito-cel utilizes Arcellx's novel D-Domain binder technology and is on track for commercial launch in 2026 pending regulatory approval.
- The CAR-T cell therapy industry has raised over $141.2 billion through various financing mechanisms, with estimates suggesting total industry funding could reach $281.7 billion when including undisclosed deals. - More than 170 companies worldwide are developing CAR-T products with 1,944 therapies in development, while 13 CAR-T cell therapies have received regulatory approval globally since 2017. - Despite a slowdown in IPOs and M&A activity in 2024, venture capital funding remains strong with 89 CAR-T companies securing $7.7 billion since 2014, supporting advancement in both blood cancer and solid tumor applications.
